ArticleReproductive sciences (Thousand Oaks, Calif.)2026
PCK2 Promotes Ribosome Biogenesis in Cervical Cancer Cells via Interaction with hnRNPK.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mitochondrial phosphoenolpyruvate carboxykinase (PCK2) is a key rate-limiting enzyme in gluconeogenesis. In cancers originating from non-gluconeogenic organs, PCK2 often exhibits a pro-tumorigenic effect, primarily through metabolic reprogramming. Through cancer database analyses and validation using tissue samples from patients with cervical cancer, we found that PCK2 exhibits oncogenic activity in cervical cancer and is localized in ribosomes within cervical cancer cells. A combination of in vitro cellular experiments, in vivo xenograft models, molecular biology techniques, transcriptomic and proteomic sequencing revealed a novel mechanism by which PCK2 drives cervical cancer progression: PCK2 enhances translational efficiency by directly interacting with the ribosome-associated protein hnRNPK. This newly identified oncogenic role of PCK2 expands our understanding of its function and provides a mechanistic foundation for its contribution to tumorigenesis in cancers arising from non-gluconeogenic tissues.
Indexed as
Identifiers
42443589What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.